Chuck, I understand what is required. Without a partner or a protease/ polymerase inhibitor to throw in the mix- what's required now is a Ph2b HCV oral study with BIT225 + ribavirin on a significant size sample group across different genotypes, or an HCV/HIV co-effected study. IMO
I'm saying that Biotron doesn't have the funds to run BIT225 in this type of trail across big sample groups- They need around 20 million atleast. Therefore more capital must be raised or a partner must be found. However in order to get that partner it looks like they might need to demonstrate the effectiveness of BIT225 in a trail with a bigger sample group. Therefore here is the problem. IMO
HIV results will be interesting, and could be the saving light in terms of a partnership arrangement, and a co-effected study. However judging from the last announcement, they don't seem to be focusing on HIV results as a big turning point for the company. Infact there is very little mention of them...
BIT Price at posting:
13.0¢ Sentiment: None Disclosure: Not Held
